BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17617631)

  • 1. Tumor-associated embryonic antigen-expressing vaccines that target CCR6 elicit potent CD8+ T cell-mediated protective and therapeutic antitumor immunity.
    Biragyn A; Schiavo R; Olkhanud P; Sumitomo K; King A; McCain M; Indig FE; Almanzar G; Baatar D
    J Immunol; 2007 Jul; 179(2):1381-8. PubMed ID: 17617631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
    Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
    Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein.
    Barsoum AL; Liu B; Rohrer JW; Coggin JH; Tucker JA; Pannell LK; Schwarzenberger PO
    Biomaterials; 2009 Jun; 30(17):3091-9. PubMed ID: 19268360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions.
    Biragyn A; Kwak LW
    Immunol Rev; 1999 Aug; 170():115-26. PubMed ID: 10566146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens.
    Biragyn A; Surenhu M; Yang D; Ruffini PA; Haines BA; Klyushnenkova E; Oppenheim JJ; Kwak LW
    J Immunol; 2001 Dec; 167(11):6644-53. PubMed ID: 11714836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones.
    Rohrer JW; Barsoum AL; Coggin JH
    J Immunol; 2006 Mar; 176(5):2844-56. PubMed ID: 16493041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
    Ruffini PA; Biragyn A; Coscia M; Harvey LK; Cha SC; Bogen B; Kwak LW
    J Leukoc Biol; 2004 Jul; 76(1):77-85. PubMed ID: 15075363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers.
    Coggin JH; Barsoum AL; Rohrer JW
    Anticancer Res; 1999; 19(6C):5535-42. PubMed ID: 10697612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo.
    Le Borgne M; Etchart N; Goubier A; Lira SA; Sirard JC; van Rooijen N; Caux C; Aït-Yahia S; Vicari A; Kaiserlian D; Dubois B
    Immunity; 2006 Feb; 24(2):191-201. PubMed ID: 16473831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.
    Furumoto K; Soares L; Engleman EG; Merad M
    J Clin Invest; 2004 Mar; 113(5):774-83. PubMed ID: 14991076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis.
    Williams IR
    Ann N Y Acad Sci; 2006 Aug; 1072():52-61. PubMed ID: 17057190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
    J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites.
    Dieu MC; Vanbervliet B; Vicari A; Bridon JM; Oldham E; Aït-Yahia S; Brière F; Zlotnik A; Lebecque S; Caux C
    J Exp Med; 1998 Jul; 188(2):373-86. PubMed ID: 9670049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corneal epithelial cells and stromal keratocytes efficently produce CC chemokine-ligand 20 (CCL20) and attract cells expressing its receptor CCR6 in mouse herpetic stromal keratitis.
    Shirane J; Nakayama T; Nagakubo D; Izawa D; Hieshima K; Shimomura Y; Yoshie O
    Curr Eye Res; 2004 May; 28(5):297-306. PubMed ID: 15287366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha.
    Liao F; Rabin RL; Smith CS; Sharma G; Nutman TB; Farber JM
    J Immunol; 1999 Jan; 162(1):186-94. PubMed ID: 9886385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
    Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
    J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.